Evogene Ltd
NASDAQ:EVGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Stereotaxis Inc
AMEX:STXS
|
US |
|
Zhuzhou Smelter Group Co Ltd
SSE:600961
|
CN |
|
K
|
Koray Gayrimenkul Yatirim Ortakligi AS
IST:KGYO.E
|
TR |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (9.6), the stock would be worth $18.13 (2 166% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.4 | $0.8 |
0%
|
| Industry Average | 9.6 | $18.13 |
+2 166%
|
| Country Average | 12.7 | $24.05 |
+2 907%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
$-4.7m
|
/ |
Jan 2026
$-10.7m
|
= |
|
|
$-4.7m
|
/ |
Dec 2026
$-9.6m
|
= |
|
|
$-4.7m
|
/ |
Dec 2027
$-9.8m
|
= |
|
|
$-4.7m
|
/ |
Dec 2028
$-9.5m
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| IL |
|
Evogene Ltd
NASDAQ:EVGN
|
7m USD | 0.4 | -0.8 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -194 446.1 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
360.1B USD | 14.4 | 86.7 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188.7B USD | 14.1 | 24.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
168.6B USD | 12.1 | 19.4 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
111.5B USD | 21.1 | 28.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -581 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.2B USD | 12.9 | 17.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
43.8B EUR | 41.6 | 38.4 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.3B AUD | 10.9 | 32.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -66.6 | -61.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 7.2 |
| Median | 12.7 |
| 70th Percentile | 21.8 |
| Max | 361.2 |
Other Multiples
Evogene Ltd
Glance View
Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
